A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies-Reference-Cited by-同舟云学术

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Published:2016-01-28 Issue:4 Volume:127 Page:411-419
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Walter Harriet S.¹^ORCID,Rule Simon A.²,Dyer Martin J. S.¹^ORCID,Karlin Lionel³,Jones Ceri⁴,Cazin Bruno⁵,Quittet Philippe⁶,Shah Nimish²,Hutchinson Claire V.¹²,Honda Hideyuki⁷,Duffy Kevin⁸,Birkett Joseph⁸,Jamieson Virginia⁸,Courtenay-Luck Nigel⁸,Yoshizawa Toshio⁷,Sharpe John⁸,Ohno Tomoya⁷,Abe Shinichiro⁸,Nishimura Akihisa⁷,Cartron Guillaume⁶,Morschhauser Franck⁵,Fegan Christopher⁴,Salles Gilles³^ORCID

Affiliation:

1. Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom;

2. Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, United Kingdom;

3. Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d’Hématologie, Pierre-Bénite, Université Claude Bernard Lyon 1, Lyon, France;

4. Cardiff CLL Research Group, School of Medicine, Heath Park, Cardiff, Wales, United Kingdom;

5. Department of Clinical Hematology, Centre Hospitalier Régional Universitaire (CHRU) de Lille, and Unité Groupe de Recherche sur les Formes Injectables et les Technologies Associées (GRITA), Université de Lille 2, Lille, France;

6. Department of Clinical Hematology and Unité Mixte de Recherche (UMR)–Centre National de la Recherche Scientifique (CNRS) 5235, CHRU, Montpellier, France;

7. ONO Pharmaceuticals Co Ltd, Osaka, Japan; and

8. ONO Pharma UK Ltd, London, United Kingdom

Abstract

Key Points We report a first-in-human dose-escalation study in relapsed/refractory B-cell malignancies with the potent BTK inhibitor ONO/GS-4059. ONO/GS-4059 induced clinically durable responses in relapsed/refractory B-cell malignancies without significant toxicities.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/4/411/1395507/411.pdf

Reference30 articles.

1. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.;Mohamed;Immunol Rev,2009

2. The Bruton’s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages.;de Weers;Eur J Immunol,1993

3. Structure of the PH domain and Btk motif from Bruton’s tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia.;Hyvönen;EMBO J,1997

4. Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk.;Saito;J Biol Chem,2001

5. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man.;Hendriks;Expert Opin Ther Targets,2011

Cited by 235 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments;Advances in Rheumatology;2024-08-21

2. Synthesis and Biochemical Evaluation of Ethanoanthracenes and Related Compounds: Antiproliferative and Pro-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL);Pharmaceuticals;2024-08-05

3. Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-07-10

4. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-03-27

5. Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia;2024-03-22